



## **Emergent BioSolutions to Present at BIO CEO & Investor Conference on February 11, 2008**

February 7, 2008

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 7, 2008--Emergent BioSolutions Inc. (NYSE:EBS), announced today that the company will be presenting at the 10th Annual BIO CEO & Investor Conference on Monday February 11, 2008 at 1:15 PM Eastern at the Waldorf Astoria Hotel in New York City. A member of the company's senior management team will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

A webcast of this presentation will be available both live and by replay. To access either the live or archived webcast, please proceed to [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), and click on the "Investors" link the day of the presentation.

An archived replay of the webcast will be available 24 hours after the live presentation.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

CONTACT: Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt

Director, Corporate Communications

301-795-1800

SchmittT@ebsi.com

SOURCE: Emergent BioSolutions Inc.